Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Trial Profile

Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs Decitabine (Primary) ; MBG 453 (Primary) ; Spartalizumab (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Jun 2018 Number of arms has been changed from 3 to 5. Planned patient number has been changed from 70 to 175.
    • 18 Jun 2018 Planned number of patients changed from 70 to 175.
    • 18 Jun 2018 Planned End Date changed from 19 Aug 2019 to 1 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top